ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IDIX (MM)

24.50
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
(MM) NASDAQ:IDIX NASDAQ Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 24.50 0.00 01:00:00

Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference and 2006 Citigroup Healthcare Conference

08/02/2006 1:30pm

PR Newswire (US)


(MM) (NASDAQ:IDIX)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more (MM) Charts.
CAMBRIDGE, Mass., Feb. 8 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced today that Jean-Pierre Sommadossi, Ph.D., Idenix's chairman and chief executive officer, will present a corporate overview at the upcoming BIO CEO & Investor Conference on Wednesday, February 15, 2006 at 12:00 p.m. at the Waldorf Astoria, New York and at the 2006 Citigroup Healthcare Conference on Tuesday, February 28, 2006 at 3:05 p.m. at the Mayflower Hotel, Washington, D.C. The live and archived webcasts of the presentations can be accessed under "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com/. The archived replays will be available on the Idenix website for two weeks following the presentations. About Idenix Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus (HIV). Idenix's headquarters are located in Cambridge, Massachusetts and it has drug discovery operations in Montpellier, France and Cagliari, Italy. Contacts: Idenix Pharmaceuticals, Inc. Amy Sullivan (617) 995-9838 Teri Dahlman (617) 995-9905 First Call Analyst: FCMN Contact: DATASOURCE: Idenix Pharmaceuticals, Inc. CONTACT: Amy Sullivan, +1-617-995-9838, or Teri Dahlman, +1-617-995-9905, both of Idenix Pharmaceuticals, Inc. Web site: http://www.idenix.com/

Copyright

1 Year (MM) Chart

1 Year (MM) Chart

1 Month (MM) Chart

1 Month (MM) Chart

Your Recent History

Delayed Upgrade Clock